Global Chorioretinitis Treatment Market, By Treatment (Medication, Surgery, Others), Diagnosis (Blood Tests, Physical Examination, Others), Symptoms (Pain or Redness in Eye, Sensation of Sparks, Sensitivity to Light, Impaired Night Vision, Excessive Tearing, Impaired Color Vision, Blurred Vision, Distortion of Objects, Others), Dosage (Injection, Tablets, Eye Drops, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Industry Trends and Forecast to 2029.
Global Chorioretinitis Treatment Market Analysis and Size
The number of cases of chorioretinitis has risen dramatically in recent years. Chorioretinitis is a kind of uveitis that affects the eye's posterior region. Various therapeutic approaches for treating inflammation in the uvea and surrounding tissues are referred to as uveitis treatment. Blurred vision, dark or floating patches in the vision, redness of the eye, and sensitivity to light are all symptoms of the condition. Nowadays, due to unhealthy lifestyle, the prevalence rate of various autoimmune and chronic diseases are increasing, this will also increases the risk of chorioretinitis. Hence, led to the introduction of chorioretinitis treatment in the market.
- Data Bridge Market Research analyses that the chorioretinitis treatment market was valued at USD 511 million in 2021 and is expected to reach USD 799.22 million by 2029, registering a CAGR of 5.75% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Chorioretinitis Treatment Market Definition
Chorioretinitis is an inflammation of the choroid, which is the inner lining of the retina. This inflammation can cause eyesight problems. The treatment's goal is to keep the patient's vision intact. If an infection is present, treatment focuses on eradicating it and suppressing the host's inflammatory reaction. Anti-inflammatory drugs are administered 48 to 72 hours after anti-infective agents are started in infective situations. Corticosteroids and immunosuppressive medications are the most common treatments for non-infectious posterior uveitis.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Medication, Surgery, Others), Diagnosis (Blood Tests, Physical Examination, Others), Symptoms (Pain or Redness in Eye, Sensation of Sparks, Sensitivity to Light, Impaired Night Vision, Excessive Tearing, Impaired Color Vision, Blurred Vision, Distortion of Objects, Others), Dosage (Injection, Tablets, Eye Drops, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Novartis AG (Switzerland), AstraZeneca (UK), Merck & Co., Inc. (US), Sumitomo Corporation (Japan), Allergan (Ireland), LEO Pharma A/S (Denmark), Cipla Inc. (US), Eli Lilly and Company (US), Bayer AG (Germany), Abbott (US), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson Private Limited (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sun Pharmaceutical Industries Ltd. (Mumbai), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US)
|
Chorioretinitis Treatment Market Dynamics
Drivers
- High prevalence rate of chronic and infectious diseases
The rise in prevalence rate of chronic and infectious diseases involving HIV/AIDS, tuberculosis, syphilis, congenital rubella and others will act as a major driver that will result in the expansion of the growth rate of the market. Along with this, increasing number of cases of autoimmune diseases such as sarcoidosis, polyarteritis nodosa and rheumatoid arthritis will propel market’s growth rate during the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of chorioretinitis treatment market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness and rising number of geriatric population are the factors that will expand the chorioretinitis treatment market. Other factors such as continuous changing lifestyle and rising level of disposable income will positively impact the chorioretinitis treatment market's growth rate. Additionally, implementation of favourable initiatives by governments to promote health will result in the expansion of chorioretinitis treatment market.
Opportunities
- Rise in the investments and research funding for chorioretinitis treatment will flourish the growth rate
Moreover, the rise in level of investments and funds for research and development activities will boost new opportunities for the market's growth rate.
Also, surging number of strategic partnership with various public and private organizations and advancement in medical technology will provide beneficial opportunities for the chorioretinitis treatment market in the forecast period of 2022-2029.
Restraints/Challenges Global Chorioretinitis Treatment Market
However, high cost associated with the treatment and lack of infrastructure in low-income countries will impede the growth rate of chorioretinitis treatment market. Additionally, complications linked with chorioretinitis and its treatment will hinder the chorioretinitis treatment market growth. Emergence of unfavourable conditions due to COVID-19 outbreak and less awareness in patients will further challenge the market in the forecast period mentioned above.
This chorioretinitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on chorioretinitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
According to epidemiological data from several research, uveitis affects 52 to 341 people per 100000 person-years in the United States. In the United States, it causes 2.8 to 10% of cases of blindness. The most prevalent cause of posterior uveitis in the globe is Toxoplasma chorioretinitis. Tropical countries with hot and humid temperatures have a higher frequency. In the United States, it accounts for 25% of all occurrences of posterior uveitis. Antibodies to Toxoplasma are found in roughly 20% of adults in the United States. Uveitis was shown to be more common as people became older. It causes an estimated 30000 new cases of legal blindness in the United States each year, accounting for around 10% to 15% of all total blindness cases in the country. Women are more likely than men to be affected by ocular inflammatory disorders, and the majority of those affected are of reproductive age.
Chorioretinitis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Chorioretinitis Treatment Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of chorioretinitis treatment in recent months.
Global Chorioretinitis Treatment Market Scope
The chorioretinitis treatment market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Medication
- Surgery
- Others
On the basis of treatment, the chorioretinitis treatment market is segmented into medication, surgery and others. Medication segment is further segmented into corticosteroids, immunosuppressive agents, anti-inflammatory agents, anti-infective agents and others. Surgery segment is further segmented into pars plana vitrectomy, laser photocoagulation and cryotherapy.
Diagnosis
- Blood Tests
- Physical Examination
- Others
On the basis of diagnosis, the chorioretinitis treatment market is segmented into blood tests, physical examination and others.
Symptoms
- Pain or Redness in Eye
- Sensation of Sparks
- Sensitivity to Light
- Impaired Night Vision
- Excessive Tearing
- Impaired Color Vision
- Blurred Vision
- Distortion of Objects
- Others
On the basis of symptoms, the chorioretinitis treatment market is segmented into pain or redness in eye, sensation of sparks, sensitivity to light, impaired night vision, excessive tearing, impaired color vision, blurred vision, distortion of objects and others.
Dosage
- Injection
- Tablets
- Eye Drops
- Others
On the basis of dosage, the chorioretinitis treatment market is segmented into injection, tablets, eye drops and others.
Route of Administration
- Oral
- Parenteral
- Topical
- Others
On the basis of route of administration, the chorioretinitis treatment market is segmented into oral, parenteral, topical and others.
End Use
- Clinic
- Hospital
- Others
On the basis of end-users, the chorioretinitis treatment market is segmented into clinic, hospital and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The chorioretinitis treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Chorioretinitis Treatment Market Regional Analysis/Insights
The chorioretinitis treatment market is analysed and market size insights and trends are provided by country, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the chorioretinitis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the chorioretinitis treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region.
Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the increasing patient pool, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Chorioretinitis Treatment Market Share Analysis
The chorioretinitis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to chorioretinitis treatment market.
Some of the major players operating in the chorioretinitis treatment market are Novartis AG (Switzerland), AstraZeneca (UK), Merck & Co., Inc. (US), Sumitomo Corporation (Japan), Allergan (Ireland), LEO Pharma A/S (Denmark), Cipla Inc. (US), Eli Lilly and Company (US), Bayer AG (Germany), Abbott (US), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson Private Limited (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sun Pharmaceutical Industries Ltd. (Mumbai), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd. (Switzerland), and Mylan N.V. (US), among others.
Research Methodology : Global Chorioretinitis Treatment Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-chorioretinitis-treatment-market
SKU-